Aristides Anastasakis

Aristides (Aris) Anastasakis
Dr. Aristides Anastasakis, MD, PhD, is a consultant cardiologist specialized in Inherited and Rare Cardiovascular Diseases. He was trained in Athens and London. He holds a Degree in Medicine and his PhD thesis was in the field of cardiomyopathies. Since 1997, is dynamically involved in the area of inherited cardiovascular diseases (“Pheidippides” program 1997 – 2004, EKKAN 2004 – 2017) and now holds the position of Scientific Director in the Unit of Inherited and Rare Cardiovascular Diseases, Onassis Cardiac Surgery Centre. He has been a member of ESC Task Force in Sports Cardiology (2004 – 2008) and an elected nucleus member of ESC Working Group on Myocardial and Pericardial Diseases (2012 – 2016). Ηe represented Greece (2015 – 2017) in EUCERD (European Union Committee of Experts on Rare Diseases) and is an elected President (2018 – 2020) on Cardiomyopathy and Inherited cardiovascular diseases working group of the Hellenic Cardiac Society, as well as the President (2017 – 2021) of the National Council of Rare Diseases in Greece. He has been awarded with several grants and actively involved in international research projects (such as HCM Investigator Outcomes). Dr. Anastasakis has a significant volume of publications in international scientific journals, chapters in medical books and is the editor of the textbook “Heart diseases in adolescence”. He is also a Board member for various scientific journals such as Hellenic Cardiac Society Journal, Cardiogenetics and Echo Research. Currently, he is the Coordinator of National Network in Precision Medicine in Cardiology (GR icardiac Net) and Board member of International Cardiomyopathy Network (ICON)

Publications per year

    1. Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report
      Domenico Corrado, Aris Anastasakis, Cristina Basso, Barbara Bauce, Carina Blomström-Lundqvist, Chiara Bucciarelli-Ducci, Alberto Cipriani, Carlo De Asmundis, Estelle Gandjbakhch, Juan Jiménez-Jáimez, Maria Kharlap, William J McKenna, Lorenzo Monserrat, James Moon, Antonis Pantazis, Antonio Pelliccia, Martina Perazzolo Marra, Kalliopi Pillichou, Jeanette Schulz-Menger, Ruxandra Jurcut, Petar Seferovic, Sanjay Sharma, Jacob Tfelt-Hansen, Gaetano Thiene, Thomas Wichter, Arthur Wilde, Alessandro Zorzi
      Int J Cardiol . 2024 Jan 15:395:131447 (read article)
    2. Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry
      Juan Pablo Kaski, Gabrielle Norrish, Juan Ramon Gimeno Blanes, Philippe Charron, Perry Elliott, Luigi Tavazzi, Michal Tendera, Cécile Laroche, Aldo P Maggioni, Anwar Baban, Diala Khraiche, Lidia Ziolkowska, Giuseppe Limongelli, Tiina Ojala, Matthias Gorenflo, Aris Anastasakis, Shaimaa Mostafa, Alida L P Caforio; EORP Paediatric Cardiomyopathy Registry Investigators
      Eur Heart J . 2024 Apr 21;45(16):1443-1454. (read article)
    3. Epidemiology of Pediatric Cardiomyopathy in a Mediterranean Population
      Alena Bagkaki, Fragiskos Parthenakis, Gregory Chlouverakis, Aris Anastasakis, Ioannis Papagiannis, Emmanouil Galanakis, Ioannis Germanakis
      Children (Basel) . 2024 Jun 15;11(6):732 (read article)
    4. Corrigendum to 'Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management' [International Journal of Cardiology, 2023, 41:180-186]
      Michele Brignole, Franco Cecchi, Aris Anastasakis, Lia Crotti, Jean Claude Deharo, Perry M Elliott, Artur Fedorowski, Juan Pablo Kaski, Giuseppe Limongelli, Martin S Maron, Iacopo Olivotto, Steve R Ommen, Gianfranco Parati, Win Shen, Andrea Ungar, Arthur Wilde
      Int J Cardiol . 2024 Feb 15:397:131589 (read article)
    5. A cost-effectiveness analysis of hypertrophic cardiomyopathy sudden cardiac death risk algorithms for implantable cardioverter defibrillator decision-making
      Nathan Green, Yang Chen, Constantinos O'Mahony, Perry M Elliott, Roberto Barriales-Villa, Lorenzo Monserrat, Aristides Anastasakis, Elena Biagini, Juan Ramon Gimeno, Giuseppe Limongelli, Menelaos Pavlou, Rumana Z Omar
      Eur Heart J Qual Care Clin Outcomes . 2024 Jun 20;10(4):285-293. (read article)
    1. Cardiomyopathies in children: An overview.
      Tsatsopoulou A, Protonotarios I, Xylouri Z, Papagiannis I, Anastasakis A, Germanakis I, Patrianakos A, Nyktari E, Gavras C, Papadopoulos G, Meditskou S, Lazarou E, Miliou A, Lazaros G.
      Hellenic J Cardiol. 2023 July–August 2023. (read article)
    2. Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy.
      Gartzonikas IK, Naka KK, Anastasakis A.
      Hellenic J Cardiol. 2023 Mar-Apr;70:65-74. (read article)
    3. Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management.
      Brignole M, Cecchi F, Anastasakis A, Crotti L, Deharo JC, Elliott PM, Fedorowski A, Kaski JP, Limongelli G, Maron MS, Olivotto I, Ommen SR, Parati G, Shen W, Ungar A, Wilde A.
      Int J Cardiol. 2023 Jan 1;370:330-337. (read article)
    4. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry.
      Lopes LR, Losi MA, Sheikh N, Laroche C, Charron P, Gimeno J, Kaski JP, Maggioni AP, Tavazzi L, Arbustini E, Brito D, Celutkiene J, Hagege A, Linhart A, Mogensen J, Garcia-Pinilla JM, Ripoll-Vera T, Seggewiss H, Villacorta E, Caforio A, Elliott PM; Cardiomyopathy Registry Investigators Group.
      Eur Heart J Qual Care Clin Outcomes. 2022 Dec 13;9(1):42-53. (read article)
    5. Clinical significance of small nerve fiber involvement in the early diagnosis and treatment of patients with Fabry disease
      Panagiotis Kokotis, Christina Zompola, Aris Anastasakis, Aikaterini Damianaki, Chrysanthi Bountziouka, Margarita Mpora, Stathis Papatheodorou, Georgios Tsivgoulis
      J Neurol Sci . 2023 Oct 15:453:120776 (read article)
    6. Impaired cerebral autoregulation in Fabry disease: A case-control study
      Lina Palaiodimou, Georgia Papagiannopoulou, Eleni Bakola, Marianna Papadopoulou, Panagiotis Kokotis, Christos Moschovos, Agathi-Rosa Vrettou, Eleni Kapsia, Dimitrios Petras, Aris Anastasakis, Sophia Lionaki, Charalambos Vlachopoulos, Ioannis N Boletis, Christina Zompola, Georgios Tsivgoulis
      J Neuroimaging . 2023 Jul-Aug;33(4):582-589 (read article)
    7. A truncating variant altering the extreme C-terminal region of desmoplakin (DSP) suggests the crucial functional role of the region: a case report study
      Malena P Pantou, Polyxeni Gourzi, Vasiliki Vlagkouli, Efstathios Papatheodorou, Alexandros Tsoutsinos, Eva Nyktari, Dimitrios Degiannis, Aris Anastasakis
      BMC Med Genomics . 2023 May 4;16(1):95. (read article)
    8. Transthyretin (Pro24Ser) variant amyloidosis: A case report of the first patient in Greece
      Ioannis Panagiotopoulos, Efstathios Papatheodorou, Aris Anastasakis, Eustathios Kastritis, Polyxeni Gourzi, Zoi Kontogeorgiou, Georgios Koutsis, Georgia Karadima, Maria Koutelou
      Hell J Nucl Med . 2023 May-Aug;26(2):145-149 (read article)
    1. D313Y Variant in Fabry Disease: A Systematic Review and Meta-analysis.
      Palaiodimou L, Stefanou MI, Bakola E, Papadopoulou M, Kokotis P, Vrettou AR, Kapsia E, Petras D, Anastasakis A, Xifaras N, Karachaliou E, Touloumi G, Vlachopoulos C, Boletis IN, Giannopoulos S, Tsivgoulis G, Zompola C.
      Neurology. 2022 Nov 8;99(19):e2188-e2200. (read article)
    2. Atrial fibrillation in hypertrophic cardiomyopathy - A contemporary mini-review.
      Dragasis S, Vlachos K, Kariki O, Koskina S, Zygouri A, Patsiotis IG, Anastasakis A, Athanasopoulos G, Ritsatos K, Letsas K, Efremidis M.
      Hellenic J Cardiol. 2022 Sep-Oct;67:66-72. (read article)
    3. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator.
      Protonotarios A, Bariani R, Cappelletto C, Pavlou M, García-García A, Cipriani A, Protonotarios I, Rivas A, Wittenberg R, Graziosi M, Xylouri Z, Larrañaga-Moreira JM, de Luca A, Celeghin R, Pilichou K, Bakalakos A, Lopes LR, Savvatis K, Stolfo D, Dal Ferro M, Merlo M, Basso C, Freire JL, Rodriguez-Palomares JF, Kubo T, Ripoll-Vera T, Barriales Villa R, Antoniades L, Mogensen J, Garcia-Pavia P, Wahbi K, Biagini E, Anastasakis A, Tsatsopoulou A, Zorio E, Gimeno JR, Garcia-Pinilla JM, Syrris P, Sinagra G, Bauce B, Elliott PM.
      Eur Heart J. 2022 Aug 21;43(32):3053-3067. (read article)
    4. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments.
      Orphanou N, Papatheodorou E, Anastasakis A.
      Heart Fail Rev. 2022 Jul;27(4):1173-1191. (read article)
    5. Risk and Protective Factors for Sudden Cardiac Death: An Umbrella Review of Meta-Analyses.
      Tsartsalis D, Korela D, Karlsson LO, Foukarakis E, Svensson A, Anastasakis A, Venetsanos D, Aggeli C, Tsioufis C, Braunschweig F, Dragioti E, Charitakis E.
      Front Cardiovasc Med. 2022 Jun 16;9:848021. (read article)
    6. Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy.
      Norrish G, Cleary A, Field E, Cervi E, Boleti O, Ziółkowska L, Olivotto I, Khraiche D, Limongelli G, Anastasakis A, Weintraub R, Biagini E, Ragni L, Prendiville T, Duignan S, McLeod K, Ilina M, Fernandez A, Marrone C, Bökenkamp R, Baban A, Kubus P, Daubeney PEF, Sarquella-Brugada G, Cesar S, Klaassen S, Ojala TH, Bhole V, Medrano C, Uzun O, Brown E, Gran F, Sinagra G, Castro FJ, Stuart G, Yamazawa H, Barriales-Villa R, Garcia-Guereta L, Adwani S, Linter K, Bharucha T, Gonzales-Lopez E, Siles A, Rasmussen TB, Calcagnino M, Jones CB, De Wilde H, Kubo T, Felice T, Popoiu A, Mogensen J, Mathur S, Centeno F, Reinhardt Z, Schouvey S, Elliott PM, Kaski JP.
      J Am Coll Cardiol. 2022 May 24;79(20):1986-1997. (read article)
    7. Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy.
      Norrish G, Ding T, Field E, Cervi E, Ziółkowska L, Olivotto I, Khraiche D, Limongelli G, Anastasakis A, Weintraub R, Biagini E, Ragni L, Prendiville T, Duignan S, McLeod K, Ilina M, Fernández A, Marrone C, Bökenkamp R, Baban A, Kubus P, Daubeney PEF, Sarquella-Brugada G, Cesar S, Klaassen S, Ojala TH, Bhole V, Medrano C, Uzun O, Brown E, Gran F, Sinagra G, Castro FJ, Stuart G, Vignati G, Yamazawa H, Barriales-Villa R, Garcia-Guereta L, Adwani S, Linter K, Bharucha T, Garcia-Pavia P, Siles A, Rasmussen TB, Calcagnino M, Jones CB, De Wilde H, Kubo T, Felice T, Popoiu A, Mogensen J, Mathur S, Centeno F, Reinhardt Z, Schouvey S, O'Mahony C, Omar RZ, Elliott PM, Kaski JP.
      Circ Arrhythm Electrophysiol. 2022 May;15(5):e010075. (read article)
    8. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers.
      Mazzanti A, Kukavica D, Trancuccio A, Memmi M, Bloise R, Gambelli P, Marino M, Ortíz-Genga M, Morini M, Monteforte N, Giordano U, Keegan R, Tomasi L, Anastasakis A, Davis AM, Shimizu W, Blom NA, Santiago DJ, Napolitano C, Monserrat L, Priori SG.
      JAMA Cardiol. 2022 Mar 30. (read article)
    9. The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy.
      Norrish G, Topriceanu C, Qu C, Field E, Walsh H, Ziółkowska L, Olivotto I, Passantino S, Favilli S, Anastasakis A, Vlagkouli V, Weintraub R, King I, Biagini E, Ragni L, Prendiville T, Duignan S, McLeod K, Ilina M, Fernández A, Bökenkamp R, Baban A, Drago F, Kubuš P, Daubeney PEF, Chivers S, Sarquella-Brugada G, Cesar S, Marrone C, Medrano C, Alvarez Garcia-Roves R, Uzun O, Gran F, Castro FJ, Gimeno JR, Barriales-Villa R, Rueda F, Adwani S, Searle J, Bharucha T, Siles A, Usano A, Rasmussen TB, Jones CB, Kubo T, Mogensen J, Reinhardt Z, Cervi E, Elliott PM, Omar RZ, Kaski JP.
      Eur J Prev Cardiol. 2022 Mar 30;29(4):645-653. (read article)
    10. A novel homozygous ALPK3 variant associated with cardiomyopathy and skeletal muscle involvement.
      Papadopoulos C, Kekou K, Anastasakis A, Svingou M, Malfatti E, Metay C, Chrysanthou M, Paschou C, Miliopoulos D, Efthimiadis G, Adamopoulos S, Papadimas G.
      Muscle Nerve. 2022 Mar;65(3):E7-E10. (read article)
    1. Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the country.
      Koutsis G, Kastritis E, Kontogeorgiou Z, Kartanou C, Kokotis P, Rentzos M, Breza M, Kleopa KA, Christodoulou K, Oikonomou E, Anastasakis A, Angelidakis P, Sarmas I, Kargiotis O, Tzagournissakis M, Zaganas I, Foukarakis E, Sachpekidis V, Papathoma A, Panas M, Stefanis L, Dimopoulos MA, Karadima G.
      Neuromuscul Disord. 2021 Dec;31(12):1251-1258. (read article)
    2. Atrial substrate characterization in patients with atrial fibrillation and hypertrophic cardiomyopathy: Evidence for an extensive fibrotic disease.
      Efremidis M, Bazoukis G, Vlachos K, Prappa E, Anastasakis A, Megarisiotou A, Dragasis S, Asvestas D, Mililis P, Saplaouras A, Efremidis T, Batsouli A, Zimpounoumi N, Valkanas K, Sideris A, Letsas KP.
      J Electrocardiol. 2021 Nov-Dec;69:87-92. (read article)
    3. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments.
      Orphanou N, Papatheodorou E, Anastasakis A.
      Heart Fail Rev. 2021 Jul 14:1-19. (read article)
    4. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
      Bistola V, Parissis J, Foukarakis E, Valsamaki PN, Anastasakis A, Koutsis G, Efthimiadis G, Kastritis E.
      Heart Fail Rev. 2021 Jul;26(4):861 879. (read article)
    5. A novel homozygous ALPK3 variant associated with cardiomyopathy and skeletal muscle involvement.
      Papadopoulos C, Kekou K, Anastasakis A, Svingou M, Malfatti E, Metay C, Chrysanthou M, Paschou C, Miliopoulos D, Efthimiadis G, Adamopoulos S, Papadimas G.
      Muscle Nerve. 2021 Dec 4. (read article)
    6. Arrhythmic risk stratification in hypertrophic cardiomyopathy: are we missing something?
      Gatzoulis KA, Georgopoulos S, Anastasakis A, Antoniou CK, Arsenos P, Tsiachris D, Dilaveris P, Sideris S, Tousoulis D.
      Europace. 2021 Apr 6;23(4):648-649. (read article)
    1. Proposed algorithm for return to sports in competitive athletes who have suffered COVID-19.
      Oikonomou E, Papanikolaou A, Anastasakis A, Bournousouzis E, Georgakopoulos C, Goudevenos J, Ioakeimidis N, Kanakakis J, Lazaros G, Papatheodorou S, Tsatsopoulou A, Tsonou P, Vogiatzi G, Panagiotakopoulos G, Tousoulis D, Vlachopoulos C.
      Hellenic J Cardiol. 2020 (read article)
    2. Arrhythmic Mitral Valve Prolapse: Implications for Family Screening and Sports Participation Eligibility.
      Papatheodorou E, Anastasakis A.
      J Am Coll Cardiol. 2020 Dec 1;76(22):2691 (read article)
    3. Impact of social containment measures on cardiovascular admissions and sudden cardiac death rates during Coronavirus Disease (COVID-19) outbreak in Greece.
      Vassilikos VP, Pagourelias ED, Katsos K, Zaggelidou E, Raikos N, Tzikas S, Tsavousoglou C, Kouparanis A, Anastasakis A, Papatheodorou E, Kassimis G, Ziakas A, Sianos G, Karvounis H, Kanonidis I, Spiliopoulou C.
      Hellenic J Cardiol. 2020 Sep 15:S1109-9666(20)30199-8. (read article)
    4. Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1.
      Mazzanti A, Guz D, Trancuccio A, Pagan E, Kukavica D, Chargeishvili T, Olivetti N, Biernacka EK, Sacilotto L, Sarquella Brugada G, Campuzano O, Nof E, Anastasakis A, Sansone VA, Jimenez-Jaimez J, Cruz F, Sánchez-Quiñones J, Hernandez Afonso J, Fuentes ME, Średniawa B, Garoufi A, Andršová I, Izquierdo M, Marinov R, Danon A, Expósito-García V, Garcia Fernandez A, Muñoz-Esparza C, Ortíz M, Zienciuk-Krajka A, Tavazzani E, Monteforte N, Bloise R, Marino M, Memmi M, Napolitano C, Zorio E, Monserrat L, Bagnardi V, Priori SG.
      J Am Coll Cardiol. 2020 Apr 21;75(15):1772-1784. (read article)
    5. Arrhythmic risk stratification in nonischemic dilated cardiomyopathy: The ReCONSIDER study design - A two-step, multifactorial, electrophysiology-inclusive approach.
      Gatzoulis KA, Dilaveris P, Arsenos P, Tsiachris D, Antoniou CK, Sideris S, Kolettis T, Kanoupakis E, Sideris A, Flevari P, Vassilikos V, Kappos K, Maounis T, Katsivas A, Kotsakis A, Karvounis H, Kossyvakis C, Leventopoulos G, Kalpakos D, Tousoulis D; ReCONSIDER study Investigators.
      Hellenic J Cardiol. 2020 Apr 21:S1109-9666(20)30075-0. (read article)
    6. Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European Registry.
      Lotan D, Salazar-Mendiguchía J, Mogensen J, Rathore F, Anastasakis A, Kaski J, Garcia-Pavia P, Olivotto I, Charron P, Biagini E, Baban A, Limongelli G, Ashram W, Wasserstrum Y, Galvin J, Zorio E, Iacovoni A, Monserrat L, Spirito P, Iascone M, Arad M.
      Circ Genom Precis Med. 2020 Nov 5. (read article)
    7. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria.
      Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari M, Migliore F, Pilichou K, Rampazzo A, Rigato I, Rizzo S, Thiene G, Anastasakis A, Asimaki A, Bucciarelli-Ducci C, Haugaa KH, Marchlinski FE, Mazzanti A, McKenna WJ, Pantazis A, Pelliccia A, Schmied C, Sharma S, Wichter T, Bauce B, Basso C.
      Int J Cardiol. 2020 Nov 15;319:106-114. (read article)
    8. An expert consensus document on the management of cardiovascular manifestations of Fabry disease.
      Linhart A, Germain DP, Olivotto I, Akhtar MM, Anastasakis A, Hughes D, Namdar M, Pieroni M, Hagège A, Cecchi F, Gimeno JR, Limongelli G, Elliott P.
      Eur J Heart Fail. 2020 Jul;22(7):1076-1096 (read article)
    9. Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population.
      Lorenzini M, Anastasiou Z, O'Mahony C, Guttman OP, Gimeno JR, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Garcia-Pavia P, Limongelli G, Pavlou M, Elliott PM; Hypertrophic Cardiomyopathy Outcomes investigators.
      JAMA Cardiol. 2020 Jan 1;5(1):73-80. (read article)
    1. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis.
      Domenico Corrado, Peter J van Tintelen, William J McKenna, Richard N W Hauer, Aris Anastastakis, Angeliki Asimaki, Cristina Basso, Barbara Bauce, Corinna Brunckhorst, Chiara Bucciarelli-Ducci, Firat Duru, Perry Elliott, Robert M Hamilton, Kristina H Haugaa, Cynthia A James, Daniel Judge, Mark S Link, Francis E Marchlinski, Andrea Mazzanti, Luisa Mestroni, Antonis Pantazis, Antonio Pelliccia, Martina Perazzolo Marra, Kalliopi Pilichou, Pyotr G A Platonov, Alexandros Protonotarios, Alessandra Rampazzo, Jeffry E Saffitz, Ardan M Saguner, Christian Schmied, Sanjay Sharma, Hari Tandri, Anneline S J M Te Riele, Gaetano Thiene, Adalena Tsatsopoulou, Wojciech Zareba, Alessandro Zorzi, Thomas Wichter, Frank I Marcus, Hugh Calkins, International Experts
      Eur Heart J. 2019 Oct 21. (read article)
    2. Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids).
      Norrish G, Ding T, Field E, Ziólkowska L, Olivotto I, Limongelli G, Anastasakis A, Weintraub R, Biagini E, Ragni L, Prendiville T, Duignan S, McLeod K, Ilina M, Fernández A, Bökenkamp R, Baban A, Kubuš P, Daubeney PEF, Sarquella Brugada G, Cesar S, Marrone C, Bhole V, Medrano C, Uzun O, Brown E, Gran F, Castro FJ, Stuart G, Vignati G, Barriales Villa R, Guereta LG, Adwani S, Linter K, Bharucha T, Garcia-Pavia P, Rasmussen TB, Calcagnino MM, Jones CB, De Wilde H, Toru-Kubo J, Felice T, Mogensen J, Mathur S, Reinhardt Z, O'Mahony C, Elliott PM, Omar RZ, Kaski JP.
      JAMA Cardiol. 2019 Sep 1;4(9):918-927 (read article)
    3. Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report.
      Elliott PM, Anastasakis A, Asimaki A, Basso C, Bauce B, Brooke MA, Calkins H, Corrado D, Duru F, Green KJ, Judge DP, Kelsell D, Lambiase PD, McKenna WJ, Pilichou K, Protonotarios A, Saffitz JE, Syrris P, Tandri H, Te Riele A, Thiene G, Tsatsopoulou A, van Tintelen JP.
      Eur J Heart Fail. 2019 Aug; 21(8):955-964. (read article)
    4. Mitral valve in hypertrophic cardiomyopathy: a three-dimensional transesophageal study.
      Venieri E, Aggeli C, Anastasakis A, Sambatakou H, Stefanadis C, Tousoulis D.
      Hellenic J Cardiol. 2019 Apr 17: S1109-9666(19)30003-X. (read article)
    5. Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis.
      O'Mahony C, Akhtar MM, Anastasiou Z, Guttmann OP, Vriesendorp PA, Michels M, Magrì D, Autore C, Fernández A, Ochoa JP, Leong KMW, Varnava AM, Monserrat L, Anastasakis A, GarciaPavia P, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, Omar RZ, Elliott PM.
      Heart. 2019 Apr;105(8):623-631. (read article)
    6. Mitral valve in hypertrophic cardiomyopathy: a three-dimensional transesophageal study.
      Venieri E, Aggeli C, Anastasakis A, Sambatakou H, Stefanadis C, Tousoulis D.
      Hellenic J Cardiol. 2021 Jan-Feb;62 (1):29-34. (read article)
    1. Current perspectives on the diagnosis and management of dilated cardiomyopathy Beyond heart failure: a Cardiomyopathy Clinic Doctor's point of view.
      Bakalakos A, Ritsatos K, Anastasakis A.
      Hellenic J Cardiol. 2018 Sep - Oct;59(5):254 261. (read article)
    2. Programmed ventricular stimulation predicts arrhythmic events and survival in hypertrophic cardiomyopathy.
      Gatzoulis KA, Georgopoulos S, Antoniou CK, Anastasakis A, Dilaveris P, Arsenos P, Sideris S, Tsiachris D, Archontakis S, Sotiropoulos E, Theopistou A, Skiadas I, Kallikazaros I, Stefanadis C, Tousoulis D.
      Int J Cardiol. 2018 Mar 1;254:175-181. (read article)
    3. The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies.
      Charron P, Elliott PM, Gimeno JR, Caforio ALP, Kaski JP, Tavazzi L, Tendera M, Maupain C, Laroche C, Rubis P, Jurcut R, Calò L, Heliö TM, Sinagra G, Zdravkovic M, Kavoliuniene A, Felix SB, Grzybowski J, Losi MA, Asselbergs FW, García-Pinilla JM, Salazar-Mendiguchia J, Mizia-Stec K, Maggioni AP; EORP Cardiomyopathy Registry Investigators: Anastasakis A, Biagini E, Bilinska Z, Castro FJ, Celutkiene J, Chakova N, Chmielewski P, Drago F, Frigy A, Frustaci A, Garcia-Pavia P, Hinic S, Kindermann I, Limongelli G, Medrano C, Monserrat L, Olusegun-Joseph A, Ripoll-Vera T, Rocha Lopes L, Saad A, Sala S, Seferovic PM, Sepp R, Urbano Moral JA, Villacorta E, Wybraniec M, Yotti R, Zachara E, Zorio E.
      Eur Heart J. 2018 May 21;39(20):1784-1793. (read article)
    4. Primary Dilated Hearts.
      A.Anastasakis ,C.Basso
      Int J Cardiol 2018 Apr 15;257:366-370 (read article)
    5. Sudden unexplained death in the young: epidemiology, aetiology and value of the clinically guided genetic screening.
      Anastasakis A, Papatheodorou E, Ritsatos K, Protonotarios N, Rentoumi V, Gatzoulis K, Antoniades L, Agapitos E, Koutsaftis P, Spiliopoulou C, Tousoulis D.
      Europace. 2018 Mar 1;20(3):472-480 (read article)
    1. Paradoxical low flow low gradient severe aortic stenosis in a woman with apical hypertrophy.
      Venieri E, Aggeli C, Psarros T, Anastasakis A, Zisimos K, Verveniotis A, Tousoulis D.
      Hellenic J Cardiol. 2017 Aug 10. (read article)
    2. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease.
      Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, Böhm M, Charron P, Elliott PM, Eriksson U, Felix SB, Garcia-Pavia P, Hachulla E, Heymans S, Imazio M, Klingel K, Marcolongo R, Matucci Cerinic M, Pantazis A, Plein S, Poli V, Rigopoulos A, Seferovic P, Shoenfeld Y, Zamorano JL, Linhart A.
      Eur Heart J. 2017 Sep 14;38(35):2649-2662. (read article)
    3. The subcutaneous ICD as an alternative to the conventional ICD system: Initial experience in Greece and a review of the literature.
      Sideris S, Archontakis S, Gatzoulis KA, Anastasakis A, Sotiropoulos I, Arsenos P, Kasiakogias A, Terentes D, Trachanas K, Paschalidis E, Tousoulis D, Kallikazaros I.
      Hellenic J Cardiol. 2017 Jan - Feb;58(1):4-16. (read article)
    4. Predictors of atrial fibrillation in hypertrophic cardiomyopathy.
      Guttmann OP, Pavlou M, O'Mahony C, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, Garcia-Pavia P, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators.
      Heart. 2017 May;103(9):672-678. (read article)
    1. Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy.
      O'Mahony C, Jichi F, Monserrat L, Ortiz-Genga M, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators*.
      Circ Arrhythm Electrophysiol. 2016 Jun;9(6). (read article)
    2. Response to Letter Regarding Article, "Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement".
      Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, Bauce B, Basso C, Brunckhorst C, Tsatsopoulou A, Tandri H, Paul M, Schmied C, Pelliccia A, Duru F, Estes NA 3rd, McKenna WJ, Thiene G, Marcus FI, Calkins H.
      Circulation. 2016 Mar 15;133(11) (read article)
    3. Characterizing the Molecular Pathology of Arrhythmogenic Cardiomyopathy in Patient Buccal Mucosa Cells.
      Asimaki A, Protonotarios A, James CA, Chelko SP, Tichnell C, Murray B, Tsatsopoulou A, Anastasakis A, te Riele A, Kléber AG, Judge DP, Calkins H, Saffitz JE.
      Circ Arrhythm Electrophysiol. 2016 Feb; 9(2) (read article)
    4. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases.
      Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, Duboc D, Gimeno J, de Groote P, Imazio M, Heymans S, Klingel K, Komajda M, Limongelli G, Linhart A, Mogensen J, Moon J, Pieper PG, Seferovic PM, Schueler S, Zamorano JL, Caforio AL, Charron P.
      Eur Heart J. 2016 Jun 14;37(23):1850-8 (read article)
    5. European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology.
      Elliott P, Charron P, Blanes JR, Tavazzi L, Tendera M, Konté M, Laroche C, Maggioni AP; EORP Cardiomyopathy Registry Pilot Investigators.
      Eur Heart J. 2016 Jan 7;37(2):164-73. (read article)
    6. Arrhythmic risk assessment in genotyped families with arrhythmogenic right ventricular cardiomyopathy.
      Protonotarios A, Anastasakis A, Panagiotakos DB, Antoniades L, Syrris P, Vouliotis A, Stefanadis C, Tsatsopoulou A, McKenna WJ, Protonotarios N.
      Europace. 2016 Apr;18(4):610-6. (read article)
    1. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.
      Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, Bauce B, Basso C, Brunckhorst C, Tsatsopoulou A, Tandri H, Paul M, Schmied C, Pelliccia A, Duru F, Protonotarios N, Estes NM 3rd, McKenna WJ, Thiene G, Marcus FI, Calkins H.
      Eur Heart J. 2015 Dec 7;36(46):3227-37 (read article)
    2. Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement.
      Corrado D, Wichter T, Link MS, Hauer RN, Marchlinski FE, Anastasakis A, Bauce B, Basso C, Brunckhorst C, Tsatsopoulou A, Tandri H, Paul M, Schmied C, Pelliccia A, Duru F, Protonotarios N, Estes NM 3rd, McKenna WJ, Thiene G, Marcus FI, Calkins H.
      Circulation. 2015 Aug 4;132(5):441-53 (read article)
    3. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA).
      Guttmann OP, Pavlou M, O'Mahony C, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, Garcia Pavia P, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators.
      Eur J Heart Fail. 2015 Aug;17(8):837-45. (read article)
    4. Clinical Significance of Epsilon Waves in Arrhythmogenic Cardiomyopathy.
      Protonotarios A, Anastasakis A, Tsatsopoulou A, Antoniades L, Prappa E, Syrris P, Tousoulis D, McKenna WJ, Protonotarios N.
      J Cardiovasc Electrophysiol. 2015 Nov;26(11):1204-1210 (read article)
    5. The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics.
      Mogensen J, van Tintelen JP, Fokstuen S, Elliott P, van Langen IM, Meder B, Richard P, Syrris P, Caforio AL, Adler Y, Anastasakis A, Gimeno JR, Klingel K, Linhart A, Imazio M, Pinto Y, Newbery R, Schmidtke J, Charron P.
      Eur Heart J. 2015 Jun 7;36(22):1367-70. (read article)
    6. Right ventricular cardiomyopathies: a multidisciplinary approach to diagnosis.
      Limongelli G, Rea A, Masarone D, Francalanci MP, Anastasakis A, Calabro' R, Giovanna RM, Bossone E, Elliott PM, Pacileo G
      Echocardiography. 2015 Jan;32 Suppl 1:S75-94.diagnosis (read article)
    1. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy.
      Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw rozpoznawania i postepowania w kardiomiopatii przerostowej, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H.
      Kardiol Pol. 2014;72(11):1054-126. (read article)
    2. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
      Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H.
      Eur Heart J. 2014 Oct 14;35(39):2733-79. (read article)
    3. Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
      Ristić AD, Imazio M, Adler Y, Anastasakis A, Badano LP, Brucato A, Caforio AL, Dubourg O, Elliott P, Gimeno J, Helio T, Klingel K, Linhart A, Maisch B, Mayosi B, Mogensen J, Pinto Y, Seggewiss H, Seferović PM, Tavazzi L, Tomkowski W, Charron P.
      Eur Heart J. 2014 Sep 7;35(34):2279-84. (read article)
    4. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD).
      O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; for the Hypertrophic Cardiomyopathy Outcomes Investigators.
      Eur Heart J. 2014 Aug 7;35(30):2010-20 (read article)
    5. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.
      Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM
      Heart. 2014 Mar;100(6):465-72. (read article)
    1. A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia.
      Mantziari L, Vassilikos V, Anastasakis A, Kotsaka X, Paraskevaidis S, Styliadis IH, Luria D.
      Ann Noninvasive Electrocardiol. 2013 Nov;18(6):571-6. (read article)
    2. A patient with ventricular tachycardia due to a novel mutation of the lamin A/C gene: case presentation and mini review.
      Kourgiannidis G, Anastasakis A, Lampropoulos K, Iliopoulos T.
      Hellenic J Cardiol. 2013 Jul-Aug;54(4):326-30. (read article)
    3. Sudden cardiac death: investigation of the classical risk factors in a community-based hypertrophic cardiomyopathy cohort.
      Anastasakis A, Theopistou A, Rigopoulos A, Kotsiopoulou C, Georgopoulos S, Fragakis K, Sevdalis E, Stefanadis C.
      Hellenic J Cardiol. 2013 Jul-Aug;54(4):281-8. (read article)
    4. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
      Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS.
      J Am Coll Cardiol. 2013 Apr 9;61(14) (read article)
    5. Fabry disease and cardiovascular involvement.
      Anastasakis A, Papatheodorou E, Steriotis AK.
      Curr Pharm Des. 2013;19(33):5997-6008. Review. (read article)
    6. Ventricular tachycardia in patients with family history of sudden cardiac death, normal coronaries and normal ventricular function. Can cardiac magnetic resonance add to diagnosis?
      Mavrogeni S, Anastasakis A, Sfendouraki E, Gialafos E, Aggeli C, Stefanadis C, Kolovou G.
      Int J Cardiol. 2013 Sep 30; 168(2):1532-3. (read article)
    1. Arrhythmogenic right ventricular cardiomyopathy: the challenge of genetic interpretation in clinically suspected cases.
      Anastasakis A, Vouliotis AI, Protonotarios N, Stefanadis C.
      Cardiology. 2012;123(3):190-4. (read article)
    2. Effects of Mutations and Genetic Overlap in Inherited Long-QT and Brugada Arrhythmia Syndromes.
      Kotta CM, Anastasakis A, Stefanadis C.
      Hellenic J Cardiol. 2012 Nov;53(6):439-46. (read article)
    3. Depression in patients with hypertrophic cardiomyopathy: is there any relation with the risk factors for sudden death?
      Igoumenou A, Alevizopoulos G, Anastasakis A, Stavrakaki E, Toutouzas P, Stefanadis C.
      Heart Asia. 2012 Jan 1;4(1):44-8. (read article)
    1. Anderson-Fabry disease: a cardiomyopathy that can be cured.
      Anastasakis A, Sevdalis E, Papatheodorou E, Stefanadis C.
      Hellenic J Cardiol. 2011 Jul-Aug;52(4):316-26 (read article)
    2. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey.
      Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB, Hughes DA; ACES study group. Collaborators: Anastasakis A et al.
      Heart 2011 Dec;97(23):1957-60 (read article)
    3. Specific electrocardiographic features associated with Cushing's disease.
      Krystallenia I. Alexandraki, Gregory A. Kaltsas, Apostolos-Ilias Vouliotis, Theodoros G. Papaioannou, Lauren Trisk, Athanasios Zilos, Márta Korbonits, G. Michael Besser, Aris Anastasakis, Ashley B. Grossman
      Clin Endocrinol (Oxf). 2011 May;74(5):558-64 (read article)
    4. Arrhythmogenic right ventricular cardiomyopathy/dysplasia on the basis of the revised diagnostic criteria in affected families with desmosomal mutations.
      Protonotarios N, Anastasakis A, Antoniades L, Chlouverakis G, Syrris P, Basso C, Asimaki A, Theopistou A, Stefanadis C, Thiene G, McKenna WJ, Tsatsopoulou A.
      Eur Heart J. 2011 May;32(9):1097 104 (read article)
    5. Mechanistic insights into arrhythmogenic right ventricular cardiomyopathy caused by desmocollin-2 mutations.
      Gehmlich K, Syrris P, Peskett E, Evans A, Ehler E, Asimaki A, Anastasakis A, Tsatsopoulou A, Vouliotis AI, Stefanadis C, Saffitz JE, Protonotarios N, McKenna WJ.
      Cardiovasc Res. 2011 Apr 1;90(1):77-87 (read article)
    6. Optimal branch selection in alcohol septal ablation.
      Toutouzas K, Karanasos A, Anastasakis A, Vavuranakis M, Seggewiss H, Stefanadis C, Rigopoulos A.
      Int J Cardiol. 2011 Feb 17;147(1):143-4. (read article)
    1. Recommendations for the cardiovascular screening of athletes.
      Deligiannis A, Anastasakis A, Antoniades L, Bobotis G, Geleris P, Goudevenos J, Hahalis G, Kouidi E, Kranidis A, Kremastinos D, Lekakis J, Parcharidis G, Pyrgakis V, Rontogiannis G, Stefanadis C, Styliadis I, Vardas P.
      Hellenic J Cardiol. 2010 Nov-Dec;51(6):530-7. (read article)
    2. Cardiac ion channel gene mutations in Greek long QT syndrome patients.
      Kotta CM, Anastasakis A, Gatzoulis K, Papagiannis J, Geleris P, Stefanadis C.
      J Appl Genet. 2010;51(4):515-8. (read article)
    3. Arterial Stiffness and Wave Reflections in Marathon Runners.
      Vlachopoulos C, Kardara D, Anastasakis A, Baou K, Terentes-Printzios D, Tousoulis D, Stefanadis C.
      Am J Hypertens. 2010 Sep;23(9):974-9 (read article)
    4. Recommendations for interpretation of 12-lead electrocardiogram in the athlete.
      Corrado D, Pelliccia A, Heidbuchel H, Sharma S, Link M, Basso C, Biffi A, Buja G, Delise P, Gussac I, Anastasakis A, Borjesson M, Bjørnstad HH, Carrè F, Deligiannis A, Dugmore D, Fagard R, Hoogsteen J, Mellwig KP, Panhuyzen-Goedkoop N, Solberg E, Vanhees L, Drezner J, Estes NA 3rd, Iliceto S, Maron BJ, Peidro R, Schwartz PJ, Stein R, Thiene G, Zeppilli P, McKenna WJ; Section of Sports Cardiology, European Association of Cardiovascular Prevention and Rehabilitation.
      Eur Heart J. 2010 Jan;31(2):243-59. (read article)
    5. Novel sodium channel SCN5A mutations in Brugada syndrome patients from Greece.
      Kotta CM, Anastasakis A, Gatzoulis K, Manolis AS, Stefanadis C.
      Int J Cardiol. 2010 Nov 5;145(1):45-8 (read article)
    1. Pathological electrocardiogram in a young sports champion: sign of athlete's heart or sub-clinical heart disease?
      Kounas S, Anastasakis A, Stefanadis C.
      Hellenic J Cardiol. 2009 May-Jun;50(3):221-3. (read article)
    2. ST segment "hump" during exercise testing and the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy.
      Michaelides AP, Stamatopoulos I, Antoniades C, Anastasakis A, Kotsiopoulou C, Theopistou A, Misailidou M, Fourlas C, Elliott PM, Stefanadis C.
      Ann Noninvasive Electrocardiol. 2009 Apr;14(2):158-64. (read article)
    3. Danon disease: further clinical and molecular heterogeneity.
      Sabourdy F, Michelakakis H, Anastasakis A, Garcia V, Mavridou I, Nieto M, Pons MC, Skiadas C, Moraitou M, Manta P, Elleder M, Levade T.
      Muscle Nerve. 2009 Jun;39(6):837-44. (read article)
    4. Naxos disease presenting with ventricular tachycardia and troponin elevation.
      Lazaros G, Anastasakis A, Tsiachris D, Dilaveris P, Protonotarios N, Stefanadis C.
      Heart Vessels. 2009 Jan;24(1):63-5. (read article)
    1. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis.
      Pelliccia A, Corrado D, Bjørnstad HH, Panhuyzen-Goedkoop N, Urhausen A, Carre F, Anastasakis A, Vanhees L, Arbustini E, Priori S.
      Eur J Cardiovasc Prev Rehabil. 2006 Dec;13(6):876 85. (read article)
    2. Prevention of sudden cardiac death in the young: targeted evaluation of those at risk.
      Anastasakis A, McKenna W, Stefanadis C.
      Hellenic J Cardiol. 2006 Sep-Oct;47(5):251-4. (read article)
    3. Myocardial Arrhythmogenic right ventricular cardiomyopathy caused by deletions in plakophilin-2 and plakoglobin (Naxos disease) in families from Greece and Cyprus: genotype-phenotype relations, diagnostic features and prognosis.
      Antoniades L, Tsatsopoulou A, Anastasakis A, Syrris P, Asimaki A, Panagiotakos D, Zambartas C, Stefanadis C, McKenna WJ, Protonotarios N.
      Eur Heart J. 2006 Sep;27(18):2208-16. (read article)
    4. Phenotype reveals genotype in a Greek long QT syndrome family.
      Anastasakis A, Kotta CM, Kyriakogonas S, Wollnik B, Theopistou A, Stefanadis C.
      Europace. 2006 Apr;8(4):241-4. (read article)
    1. Similarities in the profile of cardiopulmonary exercise testing between patients with hypertrophic cardiomyopathy and strength athletes.
      Anastasakis A, Kotsiopoulou C, Rigopoulos A, Theopistou A, Protonotarios N, Panagiotakos D, Mammalis N, Stefanadis C.
      Heart. 2005 Nov;91(11):1477-8. (read article)
    2. Recommendations for competitive sports participation in athletes Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology.
      Antonio Pelliccia 1, Robert Fagard, Hans Halvor Bjørnstad, Aris Anastassakis, Eloisa Arbustini, Deodato Assanelli, Alessandro Biffi, Mats Borjesson, François Carrè, Domenico Corrado, Pietro Delise, Uwe Dorwarth, Asle Hirth, Hein Heidbuchel, Ellen Hoffmann, Klaus P Mellwig, Nicole Panhuyzen-Goedkoop, Angela Pisani, Erik E Solberg, Frank van-Buuren, Luc Vanhees, Carina Blomstrom-Lundqvist, Asterios Deligiannis, Dorian Dugmore, Michael Glikson, Per Ivar Hoff, Andreas Hoffmann, Erik Hoffmann, Dieter Horstkotte, Jan Erik Nordrehaug, Jan Oudhof, William J McKenna, Maria Penco, Silvia Priori, Tony Reybrouck, Jeff Senden, Antonio Spataro, Gaetano Thiene. Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology; Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology
      Eur Heart J 2005 Jul;26(14):1422-45 (read article)
    3. Low prevalence of cardiac troponin T mutations in a Greek hypertrophic cardiomyopathy cohort.
      Miliou A, Anastasakis A, D'Cruz LG, Theopistou A, Rigopoulos A, Rizos I, Stamatelopoulos S, Toutouzas P, Stefanadis C.
      Heart. 2005 Jul;91(7):966-7. (read article)
    4. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology.
      Corrado D, Pelliccia A, Bjørnstad HH, Vanhees L, Biffi A, Borjesson M, Panhuyzen-Goedkoop N, Deligiannis A, Solberg E, Dugmore D, Mellwig KP, Assanelli D, Delise P, van-Buuren F, Anastasakis A, Heidbuchel H, Hoffmann E, Fagard R, Priori SG, Basso C, Arbustini E, Blomstrom-Lundqvist C, McKenna WJ, Thiene G; Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myovardial and Pericardial Diseases of the European Society of Cardiology.
      Eur Heart J. 2005 Mar;26(5):516-24 (read article)
    1. Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease).
      Kaplan SR, Gard JJ, Protonotarios N, Tsatsopoulou A, Spiliopoulou C, Anastasakis A, Squarcioni CP, McKenna WJ, Thiene G, Basso C, Brousse N, Fontaine G, Saffitz JE.
      Heart Rhythm. 2004 May;1(1):3-11 (read article)
    2. Clinical features of hypertrophic cardiomyopathy caused by an Arg278Cys missense mutation in the cardiac troponin T gene.
      Theopistou A, Anastasakis A, Miliou A, Rigopoulos A, Toutouzas P, Stefanadis C.
      Am J Cardiol. 2004 Jul 15;94(2):246-9. (read article)
    1. Subclinical skeletal muscle abnormalities in patients with hypertrophic cardiomyopathy and their relation to clinical characteristics.
      Anastasakis A, Karandreas N, Stathis P, Rigopoulos A, Theopistou A, Sepp R, Elliott PM, Panagiotakos DB, Stefanadis C, Toutouzas P.
      Int J Cardiol. 2003 Jun;89(2-3):249-56. (read article)
    1. Myelodysplasia and Naxos disease: a novel pathogenetic association?
      Polychronopoulou S, Tsatsopoulou A, Papadhimitriou SI, Panagiotou JP, Anastasakis A, Paterakis G, Anagnostou D, Protonotarious N, Haidas SA.
      Leukemia. 2002 Nov;16(11):2335-7. (read article)
    1. "Petrified" right ventricle in long-standing naxos arrhythmogenic right ventricular cardiomyopathy.
      Basso C, Tsatsopoulou A, Thiene G, Anastasakis A, Valente M, Protonotarios N.
      Circulation. 2001 Dec 4;104(23)changes (read article)
    2. Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin.
      Protonotarios N, Tsatsopoulou A, Anastasakis A, Sevdalis E, McKoy G, Stratos K, Gatzoulis K, Tentolouris K, Spiliopoulou C, Panagiotakos D, McKenna W, Toutouzas P.
      J Am Coll Cardiol. 2001 Nov 1;38(5):1477-84 (read article)
    1. Electromyographic evidence of subclinical myopathy in hypertrophic cardiomyopathy.
      Karandreas N, Stathis P, Anastasakis A, Rigopoulos A, Piperos P, Theopistou A, Stefanadis C, Toutouzas P.
      Muscle Nerve. 2000 Dec;23(12):1856-61. (read article)
    2. Implantable defibrillator therapy in Naxos disease.
      Gatzoulis K, Protonotarios N, Anastasakis A, Tsatsopoulou A, Vlasseros J, Gialafos J, Toutouzas P.
      Pacing Clin Electrophysiol. 2000 Jul;23(7):1176-8. (read article)
    3. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease).
      McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, Norman M, Baboonian C, Jeffery S, McKenna WJ.
      Lancet. 2000 Jun 17;355(9221):2119-24. (read article)
    1. Hypertrophic cardiomyopathy in Greece: clinical course and outcome.
      Kyriakidis M, Triposkiadis F, Anastasakis A, Theopistou A, Tocta R, Barbetseas J, Gialafos J.
      Chest. 1998 Oct;114(4):1091-6. (read article)
    2. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.
      Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG, Seidman CE. Aris Anastasakis et al.
      N Engl J Med. 1998 Apr 30;338(18):1248-57 (read article)
    3. Myocardial injury induced by radiofrequency and low energy ablation: a quantitative study of CK isoforms, CK-MB, and troponin-T concentrations.
      Katritsis DG, Hossein-Nia M, Anastasakis A, Poloniecki J, Holt DW, Camm AJ, Ward DE, Rowland E.
      Pacing Clin Electrophysiol. 1998 Jul;21(7):1410-6. (read article)
    4. Usefulness of noninvasive detection of left ventricular diastolic abnormalities during isometric stress in hypertrophic cardiomyopathy and in athletes.
      Manolas J, Kyriakidis M, Anastasakis A, Pegas P, Rigopoulos A, Theopistou A, Toutouzas P.
      Am J Cardiol. 1998 Feb 1;81(3):306-13. (read article)
    1. Changes in phasic coronary blood flow velocity profile and relative coronary flow reserve in patients with hypertrophic obstructive cardiomyopathy.
      Kyriakidis MK, Dernellis JM, Androulakis AE, Kelepeshis GA, Barbetseas J, Anastasakis AN, Trikas AG, Tentolouris CA, Gialafos JE, Toutouzas PK.
      Circulation. 1997 Aug 5;96(3):834-41. (read article)
    2. Use of troponin-T concentration and kinase isoforms for quantitation of myocardial injury induced by radiofrequency catheter ablation.
      Katritsis D, Hossein-Nia M, Anastasakis A, Poloniecki I, Holt DW, Camm AJ, Ward DE, Rowland E.
      Eur Heart J. 1997 Jun;18(6):1007-13. (read article)


Videos